NCT00626795View on ClinicalTrials.gov

Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)

PHASE2CompletedINTERVENTIONAL
Enrollment

773

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

June 30, 2009

Conditions
ImpetigoSecondarily Infected Traumatic Lesions
Interventions
DRUG

TD1414 2% cream

BID 7 days

DRUG

TD1414 2% cream

TID 7 days

DRUG

Bactroban® (mupirocin) 2% cream

BID 7 days

Trial Locations (2)

7925

Division of Dermatology, Groote Schuur Hospital, G23, Cape Town

36207

Anniston Medical Clinic, Anniston

Sponsors

Lead Sponsor

LEO Pharma
All Listed Sponsors
lead

LEO Pharma

INDUSTRY

NCT00626795 - Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL) | Biotech Hunter | Biotech Hunter